TL;DR
This study explored the utility of plasma p-tau217 as a biomarker for Alzheimer's Disease (AD) in the TANGO clinical trial. They found that baseline p-tau217 levels strongly correlate with amyloid and tau PET imaging, key AD pathologies, and predict faster clinical decline, suggesting its potential as a prognostic biomarker for AD.
What Problem Does This Paper Address?
Diagnosing Alzheimer's Disease (AD) and accurately predicting its progression can be challenging. While PET imaging can visualize AD's hallmark pathologies (amyloid plaques and tau tangles), it's invasive and expensive. The search for reliable, accessible blood-based biomarkers that can reflect these pathologies and predict disease trajectory is crucial for improving diagnosis, patient selection for clinical trials, and monitoring disease progression. This paper investigates whether plasma p-tau217, a specific form of phosphorylated tau protein, can serve as such a biomarker in the context of a clinical trial for a novel AD treatment.
Methods
The researchers analyzed plasma samples collected from participants in the TANGO Phase 2 study, which investigated the efficacy of gosuranemab, an anti-tau antibody. They measured plasma levels of p-tau217 using the ALZpath Quanterix Simoa assay and p-tau181 using a similar assay. To validate these findings against established AD pathology markers, they also utilized data from amyloid PET and tau PET imaging performed on a subset of participants. Clinical decline was assessed using standard cognitive scales like the CDR-SB, MMSE, ADAS-Cog13, and ADCS-ADL. Statistical analysis primarily involved Spearman correlation to assess the relationships between these different measures.
Datasets
The study utilized data from the TANGO Phase 2 clinical trial.
- Participants: 554 randomized participants in the TANGO trial.
- Plasma Samples: Collected at baseline and up to Week 78.
- Imaging Data:
- Amyloid PET (18F-florbetapir) from 322 participants at screening.
- Tau PET (18F-MK-6240) from 357 participants at baseline and Weeks 52 and 78.
- Clinical Data: Cognitive assessments (CDR-SB, MMSE, ADAS-Cog13, ADCS-ADL) collected at various time points.
This dataset is specific to the TANGO trial and is not a newly introduced public benchmark.
Key Insights and Ideas
- Plasma p-tau217 as a proxy for AD pathology: The strong correlations between plasma p-tau217 and both amyloid and tau PET imaging suggest that this blood biomarker can effectively reflect the underlying neuropathological hallmarks of AD. This is a significant finding as it offers a less invasive way to infer these pathologies.
- Prognostic potential: The observation that higher baseline p-tau217 levels are associated with a greater rate of clinical decline highlights its potential as a prognostic marker. This means it could help predict how quickly a patient's cognitive function might worsen.
- Complementary to p-tau181: The study confirmed a strong correlation between p-tau217 and another established AD blood biomarker, p-tau181, suggesting they might offer complementary information or reinforce each other's findings.
Key Results
- Correlation with other biomarkers: Baseline plasma p-tau217 was highly correlated with baseline plasma p-tau181 (Spearman = 0.7617, p < 0.0001).
- Correlation with PET imaging:
- Baseline p-tau217 correlated with baseline amyloid PET (Spearman = 0.4294, p < 0.0001).
- Baseline p-tau217 correlated with baseline tau PET across different Braak stages (Spearman range = 0.4075-0.6163, p < 0.0001).
- Prediction of clinical decline: Participants with higher baseline plasma p-tau217 showed a greater rate of clinical decline by Week 78.
Limitations and Future Work
- Exploratory Analysis: The authors acknowledge that this was an exploratory analysis within the TANGO trial.
- Need for further validation: They emphasize that additional studies are needed to define specific use cases and establish relevant thresholds for plasma p-tau217 as a biomarker for AD pathology, particularly for prescreening patients in clinical trials.
- Generalizability: While promising, the findings are from a specific trial population, and further research across diverse cohorts would be beneficial to confirm generalizability.
Summary updated